Deferasirox
Hemosiderosis
ShireSmall moleculePhase 4 / ApprovedDormant
A
81/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 71/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Hemosiderosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DESFERRIOXAMINE B Ain Shams University | Phase 4 | BBB |
Deferiprone Ain Shams University | Phase 4 | BB |
DESFERRIOXAMINE B Ain Shams University | Phase 2/3 | BB |
Deferasirox Novartis Pharmaceuticals | Phase 2 | B |
DESFERRIOXAMINE B Novartis Pharmaceuticals | Phase 2 | B |
Ferriprox Ain Shams University | Phase 2/3 | B |
Deferitazole Shire | Phase 2 | CCC |
Same molecule, other indications
Deferasirox is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →